Investigator determines the participant is medically stable and appropriate for study participation.
Ocular Surface Disease Index (OSDI) Total Score of at least 33 at Baseline.
UNC Dry Eye Management Scale Visual Analog Scale (UNC DEMS VAS) score of at least 3 at Baseline.
Modified Oxford Corneal Staining Score of at least 1 in at least one eye.
Snellen Corrected Distance Visual Acuity sufficient to complete protocol-defined assessments.
Written informed consent obtained before study procedures.
Willing and able to comply with study visits, study treatment, and protocol requirements.
Background therapies stable for at least 30 days before Baseline.
You may not be if
Acute ocular graft-versus-host disease or ocular disease that may interfere with efficacy assessment.
Active ocular or periocular infection, ocular malignancy, or active herpetic keratitis.
Intraocular surgery, refractive surgery, or ocular laser procedure within 6 weeks before Baseline or planned during the study.
Change in systemic immunosuppressive therapy, topical glaucoma therapy, or oral tetracycline therapy within 30 days before Baseline.
Initiation within 30 days before Baseline or during the trial of topical cyclosporine, lifitegrast, tacrolimus, autologous serum eye drops, platelet-rich plasma eye drops, amniotic membrane products, or another prescription therapy intended to treat ocular surface disease.
Participation in another investigational study within 30 days before Screening or concurrent enrollment.
